BioTime (BTX) Receives Analyst Rating

BioTime (BTX) : Zacks Investment Research ranks BioTime (BTX) as 3, which is a Hold recommendation. 2 research analysts consider that the stocks fundamentals point to a bright future, hence they rate the stock as a Strong Buy. The average broker rating of 2 research analysts is 1, which indicates as a Strong Buy.

BioTime (BTX) : The highest short term price target forecast on BioTime (BTX) is $10 and the lowest target price is $5. A total of 2 equity analysts are currently covering the company. The average price of all the analysts is $7.5 with a standard deviation of $3.54.


BioTime (NYSEMKT:BTX): After opening at $3.2, the stock dipped to an intraday low of $3.2 on Thursday. However, the bulls stepped in to buy at lower levels and pushed the stock higher. The stock touched an intraday high of $3.52 and the buying power remained strong till the end. The stock closed at $3.46 for the day, a gain of 7.12% for the day session. The total traded volume was 500,359. The stocks close on the previous trading day was $3.23.

BioTime, Inc. is a biotechnology company. The Company is focused on the field of regenerative medicine; human embryonic stem (hES) cell and induced pluripotent stem (iPS) cell technology. Regenerative medicine refers to therapies based on stem cell technology that are designed to rebuild cell and tissue function lost due to degenerative disease or injury. hES and iPS cells provide a means of manufacturing every cell type in the human body. The field of regenerative medicine includes a range of disciplines, including tissue banking, cellular therapy, gene therapy and tissue engineering. The Company is engaged to develop cell-based therapeutic products for diseases, such as neurological disorders, cancer, age related macular degeneration, orthopedic disorders, and age-related cardiovascular disease.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *